Navigation Links
Atlas Appoints David Whitaker as Operations Director

BATH, England, November 27, 2013 /PRNewswire/ --

Atlas Genetics Ltd ("Atlas" or the "Company"), a diagnostic company developing ultra-rapid point-of-care tests for a range of infectious diseases, today announces the appointment of David Whitaker as Operations Director with immediate effect.

David joins Atlas from DNA Electronics, where he worked as Manufacturing & Mechanical Engineering Manager, responsible for the development of a fully portable, point-of-care genetic test device.  This project involved a wide range of technical disciplines including microfluidics, electronics and molecular biology.  He worked closely with the acting Chief Scientific Officer on the overall management of the project and held direct responsibility for all device engineering activities.  

Prior to this, he spent five years as a Principal Consultant in PA Consulting's Technology and Innovation Practice.  During his tenure, he successfully developed and patented a range of medical devices for both big pharma and start-up companies.  Before joining PA Consulting, David worked in a variety of medical device engineering, contract engineering and consulting positions at companies including Ivax Pharmaceuticals, Futura Medical West Pharmaceuticals and Risdon Pharma.

David has First Class BEng degree in Mechanical & Manufacturing Engineering with Management from the University of Leeds.

Dr John Clarkson, Chief Executive Officer of Atlas, commented: "At Atlas, we have worked hard over the past year to enhance and develop our senior management team.  David brings considerable operational expertise which will be important as we enter a new phase of product manufacture and growth, further progressing Atlas towards becoming a first class diagnostics company."

About Atlas (

Atlas (Atlas Genetics Ltd) develops ultra-rapid point-of-care (POC) diagnostic tests for infectious diseases.  The Atlas io™ system uses patented technology based on the use of a novel electrochemical sensor that combines speed, accuracy and multiplex detection capability.  The Company has its head office and laboratory facilities near Bath.  Atlas was established in 2005 and is financed by VC, corporate and private investors including Consort Medical plc, Novartis Venture Funds, J&J Development Corporation, Life Science Partners (LSP), BB Biotech Ventures and YFM Equity Partners.  The company raised £16.9 million in series B finance in 2011.

The Atlas io™ platform

POC diagnostics offer health professionals the ability to test for medical conditions at the site of patient care.  Atlas has developed the io™ system, a flexible POC technology platform, which has been designed to accurately and quickly diagnose a wide range of medical conditions within 30 minutes.  The Atlas io™ system consists of an inexpensive test machine into which a disposable cartridge containing a patient sample is inserted.  The io™ platform is scheduled for clinical trials in 2014, followed by rollout in Europe and the United States, pending regulatory approvals.

Atlas is developing tests for a range of infectious diseases including sexually transmitted infections and hospital acquired infections.  The io™ system will initially be launched for the rapid testing of Chlamydia, allowing clinicians to test and treat patients in a single visit.  Around 40 million tests are carried out for these diseases in Europe and the US every year.  According to the European Centre for Disease Prevention and Control, Chlamydia is the most frequently reported bacterial Sexually Transmitted Infection (STI), with prevalence rates in young people between 5-10%, whilst Gonorrhoea is the second most commonly 'reported' STI.  An increasing awareness, number of reported cases and increased testing for Gonorrhoea, Trichomonasvaginalis and Mycoplasma genitalium infection means these are a logical extension to the STI test menu for the io™ platform.  The worldwide in vitro diagnostic market for infectious disease testing is estimated to be worth around US$9 billion.

Contact details:

Atlas Genetics Ltd:    
John Clarkson    
Tel: +44(0)1225-717930
FTI Consulting:    
Mo Noonan / Ben Atwell    
Tel: +44(0)207-831-3113

SOURCE Atlas Genetics Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Roka Bioscience Atlas System For Food Pathogen Detection Integrated At Department of Defense Food Analysis and Diagnostic Laboratory
2. Proteome atlas for the tuberculosis pathogen
3. Quadrant Engineering Plastic Products Assigns Production of Acetron® GP and Nylon 101 Hex/Square Rods to Atlas Fibre Company
4. Cancer Antibodies: Drug Target Atlas and Competitive Outlook
5. Roka Bioscience Kicks Off Atlas on Tour, a Mobile Demonstration Vehicle for the Food Safety Industry, at IAFP
6. CMDBioscience Appoints Tomi Sawyer to Scientific Advisory Board; Entrepreneurial Drug Hunter and Distinguished Scholar Named as Founding Chair
7. Boston Biomedical Appoints Patricia S. Andrews as Chief Commercial Officer
8. Regado Biosciences, Inc. Appoints World-Renowned Leader in Cardiovascular Research and Former Global Head of Cardiovascular Diseases for Merck & Co., to Board of Directors
9. Convoy Therapeutics Appoints Clinical Advisory Board
10. Egenix, Inc. Appoints Matthew Fury, M.D., Ph.D. to its Scientific Advisory Committee
11. Metamark Appoints Cornelius J. Merlini Chief Commercial Officer
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... Md. , Nov. 25, 2015  PharmAthene, Inc. ... Directors has adopted a stockholder rights plan (Rights Plan) ... net operating loss carryforwards (NOLs) under Section 382 of ... --> PharmAthene,s use of its NOLs ... "ownership change" as defined in Section 382 of the ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... November 25, 2015 The ... is a professional and in-depth study on the ...      (Logo: ) , ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ...
Breaking Biology Technology:
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
Breaking Biology News(10 mins):